Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatitis c Clear all

Conditions: Hepatitis C, Medication Adherence
Interventions: Intensive Models (mDOT and CGT) of HCV Care; Other
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Hepatitis C
Interventions: VX-950, ribavirin, peginterferon alfa-2a; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hepatitis C Virus (HCV) Infection
Interventions: Community health worker (CHW)/ registered nurse (RN) [CHW/RN], Clinic-based Standard of Care (cbSOC) Program (control group); Behavioral
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 7
States / cities: Los Angeles, California

Conditions: Chronic Hepatitis C
Interventions: Pegylated Interferon alfa-2b, Simeprevir, Ribavirin, Sofosbuvir; Drug
Lead sponsor: Center For Hepatitis C, Atlanta, GA; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hepatitis C
Interventions: Hepatitis C core antigen; Diagnostic Test
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Bloomington, Minnesota

Conditions: Hepatitis C, Awaiting Organ Transplant
Interventions: Sofosbuvir/velpatasvir, Monitoring; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatitis C, Chronic
Interventions: Copegus placebo, RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus], ritonavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 18
States / cities: La Jolla, California • Sacramento, California • Orlando, Florida + 14 more

Conditions: Hepatitis C, Hepatitis C, Chronic, HIV/AIDS
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hepatitis C, Chronic
Interventions: Not listed
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 158
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 89 more

Conditions: Chronic Hepatitis C
Interventions: BMS-790052, Ortho Tri-Cyclen®; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Tempe, Arizona • Austin, Texas

Conditions: Hepatitis C, Chronic
Interventions: Copegus, Pegasys, boceprevir, mericitabine, mericitabine placebo, boceprevir placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 7
States / cities: Littleton, Colorado • Chicago, Illinois • Shreveport, Louisiana + 4 more

Conditions: Hepatitis C Virus
Interventions: BMS-790052, Placebo, peginterferon alfa-2a, ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 35
States / cities: Montgomery, Alabama • La Jolla, California • Los Angeles, California + 28 more

Conditions: Hepatitis C
Interventions: MDX1106-02, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 7
States / cities: Anaheim, California • San Francisco, California • Springfield, Illinois + 4 more

Conditions: HIV Infections
Interventions: tipranavir, ritonavir; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 5
States / cities: Beverly Hills, California • Fort Lauderdale, Florida • Providence, Rhode Island + 2 more

Conditions: Hepatitis C
Interventions: Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose), Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Hepatitis C Viral Infection, Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 4
Interventions: Faldaprevir, TD-6450, Ribavirin; Drug
Lead sponsor: Trek Therapeutics, PBC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Coronado, California

Conditions: Hepatitis C, Chronic
Interventions: Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 49
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 41 more

Conditions: Viral Hepatitis C
Interventions: Telaprevir; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Hepatitis C
Interventions: Sofosbuvir, GS-5816; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis C
Interventions: Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Matching Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 41
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 35 more

Conditions: Intravenous Drug Abuse, HIV Infections
Interventions: Skin and Needle Hygiene Intervention, No intervention - assessment-only condition; Behavioral · Other
Lead sponsor: University of Northern Colorado; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Hepatitis C
Interventions: Single Ascending Dose Cohorts GS-9620, Multiple Ascending Dose Cohorts GS-9620; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 10
States / cities: Little Rock, Arkansas • DeLand, Florida • Orlando, Florida + 7 more

Conditions: Hepatitis C
Interventions: Daclatasvir, Telaprevir, Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 25
States / cities: Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 19 more

Conditions: Hepatitis C Virus Infection
Interventions: Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 99 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 8
States / cities: Dothan, Alabama • Los Angeles, California • Baltimore, Maryland + 5 more

Search by objective public record fields.

Intensive Models of HCV Care for Injection Drug Users

Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C

Development of a Community-based HCV Treatment Completion Intervention Among HCV Positive Homeless Adults

The SIM-SOF Trial for Hepatitis C

Hepatitis C Lab Testing Comparison Study

Transplanting Hepatitis C Positive Organs

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)

Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients

A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response

Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects

A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C

Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

A Study of MDX-1106 to Treat Patients With Hepatitis C Infection

Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation

Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults

A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection

A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials

Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers

Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816

A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)

Reducing Health Problems Associated With Injection Drug Use

A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C

Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study